Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

Documenti analoghi

• Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
  di: Das, Ishani, et al.
  Pubblicazione: (2019)
• Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations
  di: Jovanovic, Braslav, et al.
  Pubblicazione: (2009)
• Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous Melanoma
  di: Greene, Victoria R., et al.
  Pubblicazione: (2009)
• Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
  di: Falkenius, Johan, et al.
  Pubblicazione: (2017)
• Atypical BRAF and NRAS Mutations in Mucosal Melanoma
  di: Dumaz, Nicolas, et al.
  Pubblicazione: (2019)